Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO

被引：0

作者：

Thorsten O. Götze

Pompiliu Piso

Sylvie Lorenzen

Ulli S. Bankstahl

Claudia Pauligk

Moustafa Elshafei

Giuseppe Amato

Daniel Reim

Wolf O. Bechstein

Alfred Königsrainer

Stefan P. Mönig

Beate Rau

Matthias Schwarzbach

Salah-Eddin Al-Batran

机构：

[1] Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest,Department for General and Visceral Surgery

[2] UCT-University Cancer Center,Third Department of Internal Medicine (Hematology/Medical Oncology), Klinikum Rechts der Isar

[3] Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,Department of General Surgery and Emergency

[4] Hospital Barmherzige Brueder,Klinik und Poliklinik für Chirurgie, Klinikum rechts der Isar

[5] University of Regensburg,Department of General and Visceral Surgery

[6] Technische Universitat Munchen,Department of General

[7] Bariatrische und Metabolische Chirurgie,, Visceral Surgery and Transplantation

[8] Krankenhaus Nordwest,Service de Chirurgie viscérale

[9] University of Palermo,Department of Surgery

[10] Technische Universität München,undefined

[11] University Hospital Frankfurt,undefined

[12] University Hospital Tübingen,undefined

[13] Hôpitaux Universitaires de Genève,undefined

[14] Campus Charité Mitte,undefined

[15] Campus Virchow-Klinikum CCM/CVK,undefined

[16] Clinic for General,undefined

[17] Visceral,undefined

[18] Vascular and Thoracic Surgery,undefined

[19] Klinikum Frankfurt Höchst,undefined

来源：

BMC Cancer | / 21卷

关键词：

Gastric cancer; Gastroesophageal junction cancer; Lauren- classification; Signet ring cells; HIPEC; Hyperthermic intraperitoneal chemotherapy; FLOT- regimen; Gastrectomy; Quality of life; Cisplatin; Peritoneal carcinomatosis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 40 条

[11] Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
Goetze, Thorsten O.
Hofheinz, Ralf-Dieter
Gaiser, Timo
Schmalenberg, Harald
Strumberg, Dirk
Goekkurt, Eray
Angermeier, Stefan
Zander, Thomas
Kopp, Hans G.
Pink, Daniel
Siegler, Gabriele
Schenk, Michael
de Vita, Ferdinando
Galizia, Gennaro
Maiello, Evaristo
Bechstein, Wolf O.
Elshafei, Moustafa
Loose, Maria
Sookthai, Disorn
Brulin, Tanita
Pauligk, Claudia
Homann, Nils
Al-Batran, Salah-Eddin
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 153 - 163
[12] Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK
Al-Batran, S-E.
Lorenzen, S.
Thuss-Patience, P. C.
Schenk, M.
Goekkurt, E.
Hofheinz, R. D.
Kretzschmar, A.
Heuer, V.
Bolling, C.
Haag, G. M.
Angermeier, S.
von Weikersthal, L. Fischer
Bechstein, W. O.
Wicki, A.
Siebenhuner, A.
Waberer, L.
Irahara, N.
Pauligk, C.
Gotze, T. O.
Homann, N.
ANNALS OF ONCOLOGY, 2020, 31 : S927 - S928
[13] Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.
Hofheinz, Ralf Dieter
Haag, Georg Martin
Ettrich, Thomas Jens
Borchert, Kersten
Kretzschmar, Albrecht
Teschendorf, Christian
Siegler, Gabriele Margareta
Ebert, Matthias Philip
Goekkurt, Eray
Welslau, Manfred
Mahlberg, Rolf
Homann, Nils
Pink, Daniel
Bechstein, Wolf Otto
Reichardt, Peter
Gaiser, Timo
Sookthai, Disorn
Pauligk, Claudia
Goetze, Thorsten Oliver
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[14] Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
Al-Batran, S-E.
Haag, G. M.
Ettrich, T. J.
Borchert, K.
Kretzschmar, A.
Teschendorf, C.
Siegler, G. M.
Ebert, M.
Goekkurt, E.
Welslau, M. K.
Mahlberg, R. J. C.
Homann, N.
Pink, D.
Bechstein, W. O.
Reichardt, P.
Gaiser, T.
Sookthai, D.
Pauligk, C.
Goetze, T. O.
Hofheinz, R. D.
ANNALS OF ONCOLOGY, 2020, 31 : S899 - S899
[15] Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK
Al-Batran, Salah-Eddin
Lorenzen, Sylvie
Schenk, Michael
Thuss-Patience, Peter C.
Goekkurt, Eray
Hofheinz, Ralf
Kretzschmar, Albrecht
Bolling, Claus
Angermeier, Stefan
Wicki, Andreas
Siebenhuener, Alexander Rheinhard
Eigendorff, Ekkehard
Pink, Christin
Ettrich, Thomas Jens
Schmalenberg, Harald
Waberer, Lisa
Talbot, Jonathan
Pauligk, Claudia
Goetze, Thorsten Oliver
Homann, Nils
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[16] Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
Li, Hongli
Deng, Jingyu
Ge, Shaohua
Zang, Fenglin
Zhang, Le
Ren, Peng
Wang, Baogui
Cao, Fuliang
Deng, Ting
Liu, Rui
Ning, Tao
Yang, Yuchong
Bai, Ming
Wang, Xia
Ji, Zhi
Duan, Jingjing
Liu, Yong
Zhou, Dejun
Liang, Han
Ba, Yi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[17] Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma-A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.
Homann, Nils
Lorenzen, Sylvie
Schenk, Michael
Thuss-Patience, Peter C.
Goekkurt, Eray
Hofheinz, Ralf Dieter
Kretzschmar, Albrecht
Bolling, Claus
Angermeier, Stefan
Wicki, Andreas
Siebenhuener, Alexander Rheinhard
Lindig, Udo
Pink, Daniel
Ettrich, Thomas Jens
Schmalenberg, Harald
Waberer, Lisa
Talbot, Jonathan
Pauligk, Claudia
Goetze, Thorsten Oliver
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[18] Perioperative chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a randomized, multicenter phase 3 trial
Al-Batran, S. -E.
Pauligk, C.
Homann, N.
Schmalenberg, H.
Kopp, H. -G.
Haag, G. M.
Luley, K. B.
Schmiegel, W.
Folprecht, G.
Probst, S.
Prasnikar, N.
Thuss-Patience, P.
Fischbach, W.
Trojan, J.
Koenigsmann, M.
Goetze, T. O.
Kraus, T. W.
Battmann, A.
Moenig, S. P.
Bechstein, W.
Gaiser, T.
Tannapfel, A.
Jaeger, E.
Schuler, M.
Lindig, U.
Pohl, M.
Kasper, S.
Moehler, M.
Hofheinz, R. D.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 200 - +
[19] Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastroesophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO)
Salah-Eddin, Al-Batran
Claudia, Pauligk
Nils, Homann
Harald, Schmalenberg
Hans-Georg, Kopp
Martin, Haag Georg
Barbara, Luley Kim
Wolff, Schmiegel H.
Gunnar, Folprecht
Stephan, Probst
Nicole, Prasnikar
Peter, Thuss-Patience C.
Jorg, Trojan
Oliver, Goetze Thorsten
Johannes, Meiler
Martin, Schuler H.
Elke, Jaeger
Ralf-Dieter, Hofheinz
ANNALS OF ONCOLOGY, 2017, 28
[20] Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.
Al-Batran, Salah-Eddin
Homann, Nils
Schmalenberg, Harald
Knopp, Hans-Georg
Georg
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 →